Evidence map›Paper›PMID 33401377›Full record

ArticleInfectious disease reports2021

Prevalence of

Bijan Teja, Nafeesa Alibhai, Gordon D Rubenfeld, Linda R Taggart, Naheed Jivraj, Sameer A Hirji, Brian P O'Gara, Shahzad Shaefi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious disease reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Impact of COVID-19 prevention measures onExperimental and therapeutic medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Bijan TejaInterdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON M5B 1T8, Canada.ORCID 0000-0002-4978-6353
Nafeesa AlibhaiHonors Integrated Sciences, University of British Columbia, Vancouver, BC V6T 1Z2, Canada.
Gordon D RubenfeldInterdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON M5B 1T8, Canada.
Linda R TaggartDivision of Infectious Diseases, Department of Medicine, St. Michael's Hospital, Toronto, ON M5B 1W8, Canada.
Naheed JivrajInterdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON M5B 1T8, Canada.ORCID 0000-0002-4005-7015
Sameer A HirjiDepartment of General Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Brian P O'GaraDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Shahzad ShaefiDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
University of Toronto · CABeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USSt. Michael's Hospital · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While early empiric antibiotic therapy is beneficial for patients presenting with sepsis, the presentation of sepsis from

Indexed as

Clostridioides difficileClostridium difficilecritical care medicineleukocytosissepsis

Identifiers

PMID33401377
PMCPMC7839043
OpenAlexW3113721133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.